Courriel : bd@sidmexinovia.com
Téléphone : +918866862020
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
CB-Lin 0.25mg Tablet
Manufacturer/Marketed By : SERUM INSTITUTE OF INDIA
$1.06 $0.84
CB-Lin 0.25mg Tablet contains Cabergoline, a dopamine receptor agonist primarily used to treat conditions associated with elevated prolactin levels (hyperprolactinemia). Prolactin is a hormone produced by the pituitary gland, and...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
CABERGOLINE
Active Pharmaceutical Ingredient
CB-Lin 0.25mg Tablet
1,06 $US
0,84 $US
CB-Lin 0.25mg Tablet contains Cabergoline, a dopamine receptor agonist primarily used to treat conditions associated with elevated prolactin levels (hyperprolactinemia). Prolactin is a hormone produced by the pituitary gland, and excessive levels can lead to menstrual irregularities, infertility, and inappropriate milk production in women, and sexual dysfunction in men. This tablet works by stimulating dopamine receptors in the brain, reducing prolactin production.
Active Pharmaceutical Ingredient
Uses
• Hyperprolactinemia: CB-Lin 0.25mg Tablet is commonly prescribed to reduce elevated prolactin levels. High prolactin can disrupt reproductive functions, causing irregular periods, infertility, and lactation-related issues in women. In men, it can lead to decreased libido and erectile dysfunction. By lowering prolactin levels, this medication helps normalize hormonal balance and restores reproductive health.
• Parkinson’s Disease: It is also effective in managing certain symptoms of Parkinson’s disease. The dopamine-agonist action of the drug compensates for dopamine deficiency in the brain, improving motor control and reducing symptoms such as tremors, stiffness, and slow movement.
Benefits
CB-Lin 0.25mg Tablet primarily acts by stimulating dopamine receptors in the pituitary gland. Dopamine plays a critical role in regulating prolactin secretion. By activating these receptors, Cabergoline effectively suppresses the overproduction of prolactin, alleviating the symptoms of hyperprolactinemia.
Side Effects
Contact your doctor if you experience severe or persistent side effects. Regular monitoring and reporting of side effects can help ensure a safe treatment experience.
Most Common Side Effects
Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.
Common Side Effects
• Common Side Effects: Nausea, vomiting, headache, fatigue, stomach upset, constipation, and dizziness.
• Uncommon Side Effects: Low blood pressure, nasal congestion, mood changes, or vision disturbances.
• Rare Side Effects: Heart valve issues, shortness of breath, or leg cramps.
How To Use
Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.
Safety Advice
• Breast Feeding: This medication is not recommended during breastfeeding as it inhibits milk production.
• Alcohol: Avoid consuming alcohol while on this medication, as it may increase the risk of side effects such as dizziness or drowsiness.
• Liver: CB-Lin 0.25mg Tablet should be used cautiously in patients with liver disease, as dosage adjustments may be required.
• Lungs: CB-Lin 0.25mg Tablet should be used with caution in patients with a history of lung conditions, as it may cause or worsen fibrotic reactions.
• Driving: Exercise caution when driving or operating machinery, as CB-Lin 0.25mg Tablet may cause dizziness or lightheadedness.
• Pregnancy: Use CB-Lin 0.25mg Tablet during pregnancy only if prescribed by your doctor. Inform your healthcare provider if you are planning to conceive.
Disclaimer
Sidmex Inovia s'efforce de fournir des informations exactes et fiables. Cependant, l'ensemble du contenu de ce site web, y compris les descriptions et compositions des produits, est fourni à titre informatif uniquement et ne saurait se substituer à un avis, un diagnostic ou un traitement médical professionnel.
Il est conseillé aux utilisateurs de consulter un professionnel de santé qualifié avant toute décision médicale. Les informations fournies ne doivent pas être utilisées pour l'autodiagnostic ou l'automédication.
Tous les produits présentés sont exclusivement destinés aux professionnels (B2B) et aux demandes de renseignements en gros. Sidmex Inovia ne promeut pas la consommation directe par les particuliers et vise à soutenir, et non à remplacer, la relation entre le professionnel de santé et le patient.
Les noms de produits, marques et logos appartiennent à leurs propriétaires respectifs et leur utilisation n'implique aucune affiliation ni aucun parrainage. Sidmex Inovia décline toute responsabilité quant aux conséquences découlant de l'utilisation des informations fournies sur ce site web.


